电邮这篇文章 Regorafenib application in patients with metastatic colorectal cancer in actual clinical practice
- 作者: Sekacheva MI1, Bagmet NN1
-
隶属关系:
- B.V.Petrovskiy Russian Scientific Center of Surgery
- 期: 卷 18, 编号 3 (2016)
- 页面: 43-47
- 栏目: Articles
- URL: https://bakhtiniada.ru/1815-1434/article/view/27082
- ID: 27082
如何引用文章
全文:
详细
The problem of the treatment of metastatic colorectal cancer makes us to continue for seeking new ways of severe disease treatment. Regorafenib is the newest drug for use in patients who have received all possible variants of therapy. The efficacy and safety of regorafenib are proved by the results of randomized clinical trials. While in Russia the drug has only recently entered the market, but in the world scientists have already accumulated the wide experience of regorafenib application in actual clinical practice, that allows developing special approaches to selection and management of patients, achieving maximum results. This article showes the results of the review concerning foreign and Russian experience of the drug application.
作者简介
M Sekacheva
B.V.Petrovskiy Russian Scientific Center of Surgery
Email: sekach_rab@mail.ru
д-р мед. наук, онколог, ученый секретарь ФГБНУ РНЦХ им. акад. Б.В.Петровского 119991, Russian Federation, Moscow, Abrikosovskii per., d. 2
N Bagmet
B.V.Petrovskiy Russian Scientific Center of Surgeryд-р. мед. наук, ФГБНУ РНЦХ им. акад. Б.В.Петровского 119991, Russian Federation, Moscow, Abrikosovskii per., d. 2
参考
- Van Cutsem E, Ciardiello F, Seitz J.F et al. Results from the large, open - label phase 3b CONSIGN study of regorafenib in patients with previously treated metastatic colorectal cancer. ESMO 17th World Congress on Gastrointestinal Cancer, 01-04 July 2015, Barcelona, Spain. Ann Oncol 2015; 26 (Suppl. 4): Abstract LBA-05.
- Grothey A, Van Cutsem E, Sobrero A et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo - controlled, phase 3 trial. Lancet 2013; 381: 303-12.
- Li J, Qin S, Xu R et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double - blind, placebo - controlled, phase 3 trial. Lancet Oncol 2015; 16: 619-29.
- Ciardiello F, Falcone A, Cascinu S. et al. Sobrero Regorafenib for previously treated metastatic colorectal cancer (mCRC): Results from 683 Italian patients treated in the open - label phase 3B CONSIGN study. The European Cancer Congress 2015, Vienna, Austria: Abstract 2143.
- Van Cutsem E, Ciardiello F, Ychou M et al. Regorafenib in previously treated metastatic colorectal cancer (mCRC): Analysis of age subgroups in the open - label phase IIIb CONSIGN trial. J Clin Oncol, 2016 ASCO Annual Meeting (June 3-7, 2016). 2016; 34 (15. Suppl.): 3524.
- Adenis A, de la Fouchardiere C, Paule B et al. Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBACCA) nested within a compassionate use program. BMC Cancer 2016; 16: 412.
- Tabernero J, Lenz H.J, Siena S et al. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. Lancet Oncol 2015; 16: 937-48.
- Kopeckova K, Buchler T, Bortlicek Z et al. Regorafenib in the Real - Life Clinical Practice: Data from the Czech Registry. Target Oncol 2016.
- Zanwar S, Ostwal V, Gupta S et al. Toxicity and early outcomes of regorafenib in multiply pre - treated metastatic colorectal adenocarcinoma - experience from a tertiary cancer centre in India. Ann Transl Med 2016; 4 (4): 74.
补充文件
